Anticorps Polyclonal de lapin anti-Cytokeratin 19

Cytokeratin 19 Polyclonal Antibody for WB, IHC, IF/ICC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain

Applications

WB, IHC, IF/ICC, ELISA

Conjugaison

Non conjugué

N° de cat : 29855-1-AP

Synonymes

CK 19, CK19, KRT19, CK-19, Cytokeratin,Keratin

---

Galerie de données de validation

• 

  WB analysis using 29855-1-AP

  BxPC-3 cells were subjected to SDS PAGE followed by western blot with 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:40000 incubated at room temperature for 1.5 hours.

• 

  WB analysis of BxPC-3 using 29855-1-AP

  BxPC-3 cells were subjected to SDS PAGE followed by western blot with 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:20000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human breast cancer using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:1000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:1000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human normal colon slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:8000 (under 20x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon tissue slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:1000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon tissue slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:1000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human thyroid cancer using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human thyroid cancer tissue slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:1000 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human thyroid cancer using 29855-1-AP

  Immunohistochemical analysis of paraffin-embedded human thyroid cancer tissue slide using 29855-1-AP (Cytokeratin 19 antibody) at dilution of 1:1000 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IF Staining of HeLa using 29855-1-AP

  Immunofluorescent analysis of (-20°C Methanol) fixed HeLa cells using Cytokeratin 19 antibody (29855-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

• 

  IF Staining of A549 using 29855-1-AP

  Immunofluorescent analysis of (-20°C Methanol) fixed A549 cells using Cytokeratin 19 antibody (29855-1-AP) at dilution of 1:200 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

• 

  IF Staining of HepG2 using 29855-1-AP

  Immunofluorescent analysis of (-20°C Methanol) fixed HepG2 cells using Cytokeratin 19 antibody (29855-1-AP) at dilution of 1:400 and CoraLite®488-Conjugated AffiniPure Goat Anti-Rabbit IgG(H+L).

---

Applications testées

• Résultats positifs en WB: cellules BxPC-3, cellules HepG2, cellules HT-29, cellules MCF-7, cellules T-47D
• Résultats positifs en IHC: tissu de cancer du sein humain, tissu de cancer de la thyroïde humain, tissu de côlon humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
• Résultats positifs en IF/ICC: cellules HepG2, cellules A549, cellules HeLa

Dilution recommandée

• Western Blot (WB): WB : 1:5000-1:50000
• Immunohistochimie (IHC): IHC : 1:500-1:10000
• Immunofluorescence (IF)/ICC: IF/ICC : 1:200-1:800

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

29855-1-AP cible Cytokeratin 19 dans les applications de WB, IHC, IF/ICC, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Cytokeratin 19 Protéine recombinante Ag31469
• Nom complet: keratin 19
• Masse moléculaire calculée: 44KD
• Poids moléculaire observé: 40-44 kDa
• Numéro d’acquisition GenBank: NM_002276
• Symbole du gène: Cytokeratin 19
• Identification du gène (NCBI): 3880
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Cytokeratin 19 (CK19 or KRT19) is a type I (acidic) cytokeratin. It is an intermediate filament protein providing structural rigidity and multipurpose scaffolds in epithelial cells. CK19 is often overexpressed in various cancers (e.g., hepatocellular carcinoma [HCC], pancreatic adenocarcinoma, lung cancer) and serves as a biomarker for hepatic progenitor cells (HPCs) associated with poor prognosis in HCC patients . Additionally, CK19 expression is common in pancreatic and gastrointestinal adenocarcinomasand has been studied as a potential diagnostic and prognostic marker for pancreatic neuroendocrine tumors (PNETs), where positive CK19 expression correlates with poor prognosis. Serum CK19 fragments (e.g., CYFRA 21-1, CK19-2G2) have been investigated as tumor markers for lung and breast cancer, with preoperative levels associated with metastasis and survival.

{{ptg:RelatedPrimaryAntibodies}}